BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Lung Cancer

Interventions: Drug: BMS-986507
Drug: Osimertinib
Drug: Pembrolizumab

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 218

Registration Number: NCT06618287

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇬🇧
Local Institution - 0030, London, England, United Kingdom
🇺🇸
Local Institution - 0009, Miami, Florida, United States

and more 19 locations

A Real-World Study of Β-Thalassemia Major Treatment with Luspatercept in Taiwan

Recruiting

Conditions: β-Thalassemia Major

Interventions: Drug: Luspatercept

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT06596642

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
MacKay Memorial Hospital, Taipei, Taiwan

and more 2 locations

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Epoetin Alfa
Drug: Luspatercept

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 86

Registration Number: NCT06581055

Locations: 🇨🇳
National Taiwan University Hospital (NTUH), Taipei, Taiwan

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: BMS-986435

First Posted Date: 2024-08-29

Last Posted Date: 2024-11-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT06577259

Locations: 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Nintedanib
Drug: BMS 986278

First Posted Date: 2024-08-23

Last Posted Date: 2024-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 73

Registration Number: NCT06568458

Locations: 🇺🇸
Local Institution - 0002, Lenexa, Kansas, United States
🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Oral azacitidine

First Posted Date: 2024-08-22

Last Posted Date: 2024-08-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 112

Registration Number: NCT06565975

Locations: 🇫🇷
Kappa Sante, Paris, France

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-08-22

Last Posted Date: 2024-11-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT06566768

Locations: 🇬🇧
Local Institution - 0002, Nottingham, Nottinghamshire, United Kingdom
🇬🇧
Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Relatlimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2024-08-20

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 800

Registration Number: NCT06561386

Locations: 🇺🇸
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
🇺🇸
Local Institution - 0369, Canton, Ohio, United States
🇧🇷
Local Institution - 0382, Fortaleza, Ceará, Brazil

and more 214 locations

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-13

Last Posted Date: 2024-11-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT06551129

Locations: 🇺🇸
Analysis Group Inc., Boston, Massachusetts, United States

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 685

Registration Number: NCT06549608

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy